Affordable Access

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

Authors
Type
Published Article
Journal
The Journal of clinical endocrinology and metabolism
Publication Date
Volume
92
Issue
4
Pages
1305–1310
Identifiers
PMID: 17264176
Source
Medline
License
Unknown

Abstract

Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.

Statistics

Seen <100 times